2 QuellenVerfolgt seit 11. Sept., 23:30
STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
Berichterstattung chronologisch
Erste Meldung11. Sept., 23:30STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
STAT•Jonathan Wosen
Neueste14. Sept., 18:37FDA OKs First Drug to Target Muscle Loss in SMA
Apitegromab is the first SMA therapy to directly target muscle loss and is approved as add-on treatment for patients aged 2 years and older receiving an SMN2-targeted therapy. Medscape Medical News
Medscape